Idiopathic Pulmonary Fibrosis Clinical Trials

Recruiting Idiopathic Pulmonary Fibrosis studies

• An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
  NCT06951217PHASE2Avalyn Pharma Inc.Progressive Pulmonary FibrosisBirmingham, Alabama
• A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
  NCT07652658PHASE2AstraZenecaIdiopathic Pulmonary Fibrosis (IPF)Birmingham, Alabama
• Pulmonary Fibrosis Foundation Community Registry
  NCT05382572Pulmonary Fibrosis FoundationPulmonary FibrosisChicago, Illinois
• A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
  NCT07516951PHASE2Chiesi Farmaceutici S.p.A.Idiopathic Pulmonary FibrosisHannibal, Missouri
• Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
  NCT07671911PHASE3Trevi TherapeuticsIdiopathic Pulmonary FibrosisNewport Beach, California
• A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
  NCT06968845PHASE2Rein TherapeuticsIdiopathic Pulmonary Fibrosis (IPF)Birmingham, Alabama
• Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
  NCT07284602PHASE3PureTechIdiopathic Pulmonary Fibrosis (IPF)Palm Spring, California
• Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
  NCT07230288PHASE2AbbVieIdiopathic Pulmonary FibrosisBirmingham, Alabama
• Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
  NCT05571059PHASE2Cumberland PharmaceuticalsIdiopathic Pulmonary FibrosisLa Mesa, California
• Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
  NCT00373841University of PittsburghIdiopathic Pulmonary FibrosisPittsburgh, Pennsylvania
• Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
  NCT01915511Duke UniversityIdiopathic Pulmonary Fibrosis, Interstitial Lung DiseaseBirmingham, Alabama
• Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
  NCT04362644PHASE1University of Alabama at BirminghamIdiopathic Pulmonary FibrosisBirmingham, Alabama

See all 25 recruiting trials →

Idiopathic Pulmonary Fibrosis trials by state

• California
• Texas
• New York
• Florida
• Pennsylvania
• Massachusetts
• Ohio
• Illinois
• North Carolina
• Maryland
• Georgia
• Tennessee

Idiopathic Pulmonary Fibrosis trials by metro

• New York
• Houston
• Boston
• Chicago
• Philadelphia
• Los Angeles
• Dallas
• Atlanta
• Miami
• Nashville
• Rochester
• Baltimore

Frequently asked questions

How do I find recruiting Idiopathic Pulmonary Fibrosis clinical trials?

Browse the actively recruiting Idiopathic Pulmonary Fibrosis studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.

Are Idiopathic Pulmonary Fibrosis clinical trials free to join?

Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.

Who can take part in a Idiopathic Pulmonary Fibrosis clinical trial?

Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.